PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
0.00 - 0.01
0.00 - 0.02
1.30M / 496.9K (Avg.)
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
-82.06%
Both firms have declining sales. Martin Whitman would suspect an industry slump or new disruptive entrants.
-66.00%
Both firms have negative gross profit growth. Martin Whitman would question the sector’s viability or cyclical slump.
-123.40%
Both companies show negative EBIT growth. Martin Whitman would consider macro or sector-specific headwinds.
-123.40%
Both companies face negative operating income growth. Martin Whitman would suspect broader market or cost hurdles.
-139.08%
Negative net income growth while XRF.AX stands at 13.78%. Joel Greenblatt would push for a reevaluation of cost or revenue strategies.
-140.00%
Negative EPS growth while XRF.AX is at 12.54%. Joel Greenblatt would expect urgent managerial action on costs or revenue drivers.
-142.11%
Negative diluted EPS growth while XRF.AX is at 12.54%. Joel Greenblatt would require immediate efforts to restrain share issuance or boost net income.
1.85%
Share count expansion well above XRF.AX's 1.21%. Michael Burry would question if management is raising capital unnecessarily or is over-incentivizing employees with stock.
-0.12%
Reduced diluted shares while XRF.AX is at 1.24%. Joel Greenblatt would see a relative advantage if the competitor is diluting more.
No Data
No Data available this quarter, please select a different quarter.
129.64%
Positive OCF growth while XRF.AX is negative. John Neff would see this as a clear operational advantage vs. the competitor.
120.13%
Positive FCF growth while XRF.AX is negative. John Neff would see a strong competitive edge in net cash generation.
142.30%
Similar 10Y revenue/share CAGR to XRF.AX's 151.40%. Walter Schloss might see both firms benefiting from the same long-term demand.
-24.58%
Negative 5Y CAGR while XRF.AX stands at 74.52%. Joel Greenblatt would push for a turnaround plan or reevaluation of the company’s product line.
13.36%
3Y revenue/share CAGR under 50% of XRF.AX's 49.22%. Michael Burry might see a serious short-term decline in relevance vs. the competitor.
657.42%
10Y OCF/share CAGR above 1.5x XRF.AX's 132.15%. David Dodd would check if a superior product mix or cost edge drives this outperformance.
333.39%
Below 50% of XRF.AX's 1139.05%. Michael Burry would be alarmed about sustained underperformance in generating free operational cash.
565.52%
3Y OCF/share CAGR above 1.5x XRF.AX's 144.47%. David Dodd would confirm if the firm is quickly gaining an operational edge over the competitor.
-650.00%
Negative 10Y net income/share CAGR while XRF.AX is at 198.79%. Joel Greenblatt sees a major red flag in long-term profit erosion.
-287.50%
Negative 5Y net income/share CAGR while XRF.AX is 195.12%. Joel Greenblatt would see fundamental missteps limiting profitability vs. the competitor.
-475.00%
Negative 3Y CAGR while XRF.AX is 72.97%. Joel Greenblatt might call for a short-term turnaround strategy or cost realignment.
4382.33%
10Y equity/share CAGR above 1.5x XRF.AX's 74.40%. David Dodd would confirm if consistent earnings retention or fewer write-downs drive this advantage.
132.10%
5Y equity/share CAGR above 1.5x XRF.AX's 52.04%. David Dodd might see stronger earnings retention or fewer asset impairments fueling growth.
73.11%
3Y equity/share CAGR above 1.5x XRF.AX's 30.57%. David Dodd verifies the company’s short-term capital management far exceeds the competitor’s pace.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-100.00%
Negative near-term dividend growth while XRF.AX invests at 86.63%. Joel Greenblatt sees a weaker short-term distribution policy unless justified by strategic spending.
-41.70%
Both reduce receivables yoy. Martin Whitman suspects a shift in the entire niche’s credit approach or softer demand.
4.93%
Inventory growth well above XRF.AX's 4.59%. Michael Burry suspects overshooting production or weaker sell-through vs. the competitor.
-9.39%
Both reduce assets yoy. Martin Whitman suspects a broader sector retraction or post-boom asset trimming cycle.
-11.60%
Both erode book value/share. Martin Whitman suspects a difficult environment or poor capital deployment for both players.
-63.18%
We’re deleveraging while XRF.AX stands at 35.08%. Joel Greenblatt considers if we gain a balance-sheet advantage for potential downturns.
-100.00%
Our R&D shrinks while XRF.AX invests at 0.00%. Joel Greenblatt checks if we risk falling behind a competitor’s new product pipeline.
-1.16%
Both reduce SG&A yoy. Martin Whitman sees a cost war or cyclical slowdown forcing overhead cuts.